Raven Biotechnologies
Biopharmaceutical company focused on discovery, preclinical development, and early clinical development of monoclonal antibody–based therapeutics for oncology. Maintains integrated capabilities in protein engineering (including Fc-domain optimization), preclinical pharmacology and translational studies, biomarker assay development, and in‑house GMP biologics manufacturing and contract development/manufacturing services.
Industries
Nr. of Employees
medium (51-250)
Raven Biotechnologies
South San Francisco, California, United States, North America
Products
Pipeline of engineered antibody therapeutics for oncology
Portfolio of investigational antibody candidates including Fc‑engineered antibodies, bispecific immune‑engaging constructs, and antibody–drug conjugates under preclinical and early clinical development for solid tumors and hematologic malignancies.
Pipeline of engineered antibody therapeutics for oncology
Portfolio of investigational antibody candidates including Fc‑engineered antibodies, bispecific immune‑engaging constructs, and antibody–drug conjugates under preclinical and early clinical development for solid tumors and hematologic malignancies.
Services
Integrated antibody development and GMP manufacturing services (CDMO)
On-site services spanning antibody engineering, preclinical testing, process development, analytical testing, and GMP manufacture of clinical biologics provided as contract development and manufacturing services.
Integrated antibody development and GMP manufacturing services (CDMO)
On-site services spanning antibody engineering, preclinical testing, process development, analytical testing, and GMP manufacture of clinical biologics provided as contract development and manufacturing services.
Expertise Areas
- Monoclonal antibody therapeutics for oncology
- Protein and antibody engineering (including Fc optimization and multispecific formats)
- Bispecific and T-cell engager development
- Antibody–drug conjugate discovery and preclinical development
Key Technologies
- Surface plasmon resonance for binding kinetics
- Antigen-capture immunoassays (ELISA)
- Multiparameter flow cytometry
- Cell-based ADCC and cytotoxicity assays